Pasar al contenido principal

COMPRENSION DE LOS MECANISMOS MOLECULARES DE INMUNOMODULACION Y RESISTENCIA BACTERIANA MEDIANTE APROXIMACIONES DE LA QUIMICA COMPUTACIONAL

PID2023-152271NB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Integrated NMR-crystallography-computational approach for molecular recognition studies of human Gαi3 protein by a small molecule inhibitor

  • Ferreras-Gutiérrez, Mariola
  • Mínguez-Toral, Marina
  • Ibáñez de Opakua, Alain
  • Martín-Santamaría, Sonsoles
  • García-Marcos, Mikel
  • Medrano, Francisco Javier
  • Blanco, Francisco J.
12 p.-6 fig.-1 tab., The small molecule IGGi-11 targets Gαi subunits of heterotrimeric guanine nucleotide-binding proteins. Gα subunits are activated by G-protein-coupled receptors in response to extracellular stimuli by accelerating the exchange of GDP for GTP, but they are also activated by intracellular proteins like GIV, of which elevated levels correlate with increased cell migration and cancer metastasis. IGGi-11 disrupts the interaction of Gαi proteins with GIV and inhibits pro-invasive traits of metastatic breast cancer cells without interfering with GPCR signaling. IGGi-11 is a competitive inhibitor but binds Gαi3 with a 10-fold lower affinity than GIV. To guide the design of higher affinity inhibitors, we aimed at obtaining high-resolution structural data on the complex. To facilitate its crystallization, we have removed the most flexible residues at the chain ends of Gαi3, identified by NMR. While Gαi3 crystals grown with excess IGGi-11 did not show the bound compound, computational docking and molecular dynamics simulations identified the interactions driving the molecular recognition. This approach revealed heterogeneous binding due to the symmetry of IGGi-11 chemical structure and to the elongated shape and flexibility of the binding site. Our results suggest that chemical modifications breaking IGGi-11 symmetry might yield inhibitors with higher affinity and potential as antimetastatic drugs., This work was supported by grants PID2020-113225GB-I00 and PID2023-147699OB-I00 to FJB, grant PID2020-113588RB-I00 and PID2023-152271NB-I00 to SMS, and by the Formación de Personal Investigador contracts PRE2018-085788 to MFG and PRE2021-097247 to MMT, all funded by the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033. It was also suppported by grant R01GM147931 from the National Institutes of Health to MGM, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Exploring SARS-CoV-2 spike RBD pockets as targets for generic drugs: a combined computational, biophysical, and biological approach

  • García-Marín, Javier
  • Francés-Gómez, Clara
  • Forcada-Nadal, Alicia
  • Adhav, Anmol
  • Marco-Marín, Clara
  • Rubio, Vicente
  • Marina, Alberto
  • Llácer, José Luis
  • Geller, Ron
  • Martín-Santamaría, Sonsoles
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was a pandemic that killed over 6 million people worldwide, with devastating social and economic impacts still being felt today. Despite the recent and successful development of RNA vaccines, there remains a need for antiviral drugs to treat patients at risk for drug resistance, immunological disorders, or reduced treatment efficacy. In this regard, several computational approaches have been carried out to find small molecules targeting the SARS-CoV-2 Spike S protein, and drug repurposing strategies have been applied to find rapid and accessible candidates for clinical use. In this work, we conduct an exhaustive computational study of the receptor binding domain (RBD) of the spike S protein to identify and characterize druggable pockets and to identify generic drugs as blockers of SARS-CoV-2 entry. The combination of computational screening, biophysical studies in both the RBD (Wuhan-Hu-1 and Omicron BA.1 variants) and Spike protein (Wuhan variant), and the in vitro assays in SARS-CoV-2 Wuhan-Hu-1, Delta, and Omicron BA.1 has led to the identification of generic drugs with S protein binding properties and antiviral activity. Based on in vitro antiviral activity and mechanism of action analysis at the atomic/molecular level, fingolimod exhibited the most promising profile for a possible SARS-CoV-2 antiviral treatment., Funding for this project was provided by grants from the European Commission NextGenerationEU fund (EU 2020/2094) through CSIC’s Global Health Platform (PTI Salud Global), Crue-CSIC-Santander Fondo Supera Covid-19 “BlockAce”, and CSIC Grant (CSIC-COV19-082) to S.M.-S., R.G., V.R., A.M., and J.-L.L. J.G.-M. and S.M.-S. gratefully acknowledge BioSolveIT for providing a one-year SeeSAR license during the Scientific Challenge Summer 2020. Grants PID2020-113588RB-I00 and PID2023-152271NB-I00 to S.M.-S. and PID2020-120322RB-C21 to V.R., funded by the Spanish Ministry for Science and Innovation, are also gratefully acknowledged, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Simultaneous secretion of a PD-L1 x 4-1BB bispecific antibody improves antileukemic efficacy of STAb-T cells secreting a CD19-specific T-cell engager

  • Gómez-Rosel, Marina
  • Rubio-Pérez, Laura
  • Zagorac, Ivana
  • Domínguez-Alonso, Carmen
  • Díez-Alonso, Laura
  • Hangiu, Oana
  • Navarro, Rocío
  • Torres-Ruiz, Raúl
  • Rodriguez-Perales, Sandra
  • Blanco, Francisco J.
  • Compte, Marta
  • Álvarez-Vallina, Luis
  • Blanco, Belén
22 páginas, 5 figuras, Adoptive therapy with CAR-T cells and systemic administration of bispecific T-cell engagers (TCE) have achieved unprecedented success in the treatment of relapsed/refractory (R/R) B-cell malignancies. However, high relapse rates remain a major challenge. STAb (Secretion of T cell-redirecting bispecific Antibodies)-T-cell immunotherapy represents a promising alternative by enabling both polyclonal T-cell recruitment and sustained bispecific antibody release. Here, we describe an evolution of STAb-T19 therapy, which has demonstrated superior outcomes to those of CAR-T-19 cells in preclinical models of B-ALL, on the basis of the simultaneous secretion of two bispecific antibodies: a CD19 × CD3 TCE and a PD-L1 × 4-1BB bsAb. The combined approach aims to increase the antitumor efficacy of STAb-T19 cells by blocking the PD-1/PD-L1 axis with conditional 4-1BB costimulation to ensure the long-term persistence of STAb-T cells. Preclinical data show that this combination improves cytotoxic activity and prolongs antileukemic efficacy compared with low-dose single STAb-T therapy. Our findings suggest that the integration of PD-L1 × 4-1BB bsAbs into STAb-T19 therapy may maximize efficacy, thereby opening a promising avenue to address resistance and relapse in B-ALL. Moreover, this approach may pave the way for the development of next-generation cell-based therapies for hematologic and solid malignancies., BB is funded by Fundación Científica de la Asociación Española Contra el Cáncer (INNOV211832BLAN), the Comunidad de Madrid (IND2022/BMD−23732) and the Instituto de Salud Carlos III (ISCIII) (PI20/01030, PI23/01256). LA-V is funded by the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033 (PID2023-148429OB-I00, PID2020-117323RB-I00, PDC2021−121711-I00, CPP2022−009762, CPP2022−009765, CPP2023−010827), ISCIII (DTS20/ 00089, PMPTA22/00167), the Asociación Española contra el Cáncer (PROYE19084ALVA and PRYGN234844ALVA), the CRIS Cancer Foundation (FCRIS−2021−0090 and FCRIS−2023−0070), the Fundación ‘‘La Caixa’’ (HR21−00761 project IL7R_LungCan), the Comunidad de Madrid (P2022/BMD−7225 Next Generation CART MAD), and the Fundación FERO (BBASELGAFERO2024.01). M.G.-R. is supported by an industrial PhD fellowship from the Comunidad de Madrid (IND2022/BMD−23732). FJB is funded by PID2023-152271NB-I00 from MCIN/AEI/10.13039/501100011033. We thank the Proteomics service at CIC bioGUNE and the Molecular Interactions service at CIB-CSIC for assisting with the mass spectrometry and SEC-MALS experiments. This study has adhered to ARRIVE guidelines, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Exploring Inhibition of Bacterial Conjugation Coupling Protein TrwB: Novel Ligands to Fight Antimicrobial Resistance Spread

  • Gómez-Rubio, Elena
  • Arana, Lide
  • Vicario-Martín, Roberto
  • Arbé-Carton, Kepa
  • Garbisu, Carlos
  • Martín-Cámara, Olmo
  • Alkorta, Itziar
  • Martín-Santamaría, Sonsoles
Bacterial conjugation is the most sophisticated mechanism for horizontal gene transfer. Conjugative plasmids allow the recipient bacterium to acquire new traits from the donor, such as antimicrobial resistance (AMR). Among the proteins involved in the plasmid transfer machinery, the Type IV Coupling Protein (T4CP) links the relaxosome and the Type IV Secretion System (T4SS). However, despite their biological relevance and their potential as a target to control AMR, only a few T4CPs have been exhaustively studied. The archetype of the T4CP family is the coupling protein of the conjugative plasmid R388, TrwB. The inhibition of TrwB ATPase activity or oligomerization with small-molecule modulators is expected to control the transfer of R388, contributing to combat AMR spread. Following a drug repurposing approach, we have combined in silico screening studies, molecular dynamics (MD) simulations, and in vitro bacterial conjugation assays to identify a small collection of compounds that selectively decrease the frequency of conjugation of the plasmid R388 (30-40%). Our results suggest that this inhibition is the result of the specific interaction of these drugs with TrwB. The search for conjugation inhibitors, via the inactivation of proteins such as T4CPs, rises as a strategy to advance in solutions to combat the silent pandemic of AMR., This work was supported by grants PID2020-113588RB-I00, PID2020-116495RB-I00, and PID2023-152271NB-I00 from the Spanish Ministry of Science and Innovation and Grant IT1578-22 from the Department of Education of the Basque Government., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synthesis of Polyhydroxylated Pyrrolidinyl Analogs of Sugar Nucleotides. Experimental and Computational Studies on Their Interactions With GalNAC-T's

  • Merino, Pedro
  • Juste, Veronica
  • Montesa, Alejandro
  • Pereira, Sandra
  • Orta, Sara
  • Pedrón, Manuel
  • Jiménez, Ana I.
  • Martín-Santamaría, Sonsoles
  • Hurtado-Guerrero, Ramón
  • Delso, Ignacio
  • Tejero, Tomás
Direct coupling between polyhydroxylated pyrrolidinyl β-amino phosphonates and uridine monophosphate (UMP) yields polyhydroxylated pyrrolidinyl analogs of sugar nucleotides suitable inhibitors of N-acetyl-galactosyltransferases. β-Amino phosphonates have been synthesized in an enantiomerically pure form through the nucleophilic addition of a phosphonate to polyhydroxylated cyclic nitrones. The reaction has been studied in detail and excellent diastereoselectivities are obtained in agreement with a stereochemical model well supported by density functional theory calculations. Binding of the nucleotide analogs with N-acetylgalactosyltransferases GalNAc-T2, GalNAc-T14, and GalNAc-T16 has been studied both experimentally and computationally through molecular dynamics simulations. Saturation transfer difference nuclear magnetic resonance experiments and measurement of Kd values have been used to validate the binding model at the active site. These studies provide important information of the role of the pyrophosphate and pyrrolidinyl moieties on the observed affinity, We thank Ministerio de Ciencia e Innovacion (MICINN, Spain) (Projects PID2022-137973NB-I00 and PID2019-104090RB-I00 to P.M.; PID2022 136362NB-I00 to R.H.-G. and PID2020-113588RB-I00 and PID2023 152271NB-I00 to S.M.-S.) and Government of Aragón (Spain) (Grupos Consolidados, E34_20R) for financial support. V.J. and S.P. thank also MICINN for FPI predoctoral contracts. A.M., M.P., and S.O. thank Government of Aragon for predoctoral contracts., Peer reviewed, Sin experimentacion animal ni uso de NAMs
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting toll-like receptors in the immunotherapy era: the chemistry behind TLR modulators

  • Mínguez-Toral, Marina
  • Fernández-Vasco, Gema
  • Furjun, Ameerah B.
  • Matamoros-Recio, Alejandra
  • Martín-Cámara, Olmo
  • Martín-Santamaría, Sonsoles
Toll-like receptors (TLRs) comprise a family of transmembrane pattern-recognition receptors that sense pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), thereby orchestrating innate immune responses. Over the past decade, TLRs have emerged as promising therapeutic targets for infectious, inflammatory, autoimmune, and oncological diseases. This review provides a comprehensive overview of TLR agonists and antagonists reported in the last ten years, highlighting an exceptional range of chemical classes, including peptides, nucleic acids, glycolipids, lipopeptides, and small molecules. We discuss the structural determinants underlying receptor selectivity, the design strategies enabling functional modulation, and the progress in preclinical and clinical development. We also address emerging trends, remaining challenges, and opportunities for the rational design of next-generation TLR modulators with improved selectivity and therapeutic potential., Funding from the Spanish Ministry of Science and Innovation (PID2020-113588RB-I00, PID2023-152271NB-I00, PRE2018-086249, PRE2021-097247, PREP2023-002126, and PCI2025-163261 MICIU/AEI/10.13039/501100011033/UE) and European Commission (ERA4Health Partnership NANOTECMEC 2024. Ref. “NextNano4Cancer” GA No. 101095426 of the EU Horizon Europe Research and Innovation Programme) are gratefully acknowledged., Peer reviewed